EL PASO, Texas (KFOX14/CBS4) — Scientists at The University of Texas at El Paso have identified a promising new target in the battle against high-grade serous carcinoma, a particularly aggressive form of ovarian cancer.
According to the research team, less than 50% of women survive five years after being diagnosed with this type of cancer.
A study published in “Scientific Reports” reveals that Claudin-4, a protein that increases in ovarian cancer, may contribute to the cancer’s resistance by helping tumors evade the body’s immune system.
The study was led by UTEP postdoctoral researcher Fabian R. Villagomez, Ph.D., and Benjamin G. Bitler, Ph.D., from the University of Colorado Anschutz.
The researchers used animal models with immune systems similar to humans to study the tumors. They found that targeting Claudin-4 enhanced the immune system’s ability to locate and attack the tumors, making the cancer more susceptible to treatment, UTEP officials said.
Villagomez explained, “Claudin-4 seems to help the tumor deal with these genetic changes, allowing it to survive, hide from the immune system, and avoid cell death.” He works in the Department of Biological Sciences at the UTEP College of Science.
The team tested a peptide called CMP, which can block Claudin-4, in combination with a PARP inhibitor, a drug commonly used to treat ovarian cancer. The combination proved effective, slowing tumor growth and improving the immune system’s ability to combat the cancer.
Although the treatment has not yet been tested in humans, Villagomez plans to continue his research on ovarian cancer and Claudin-4. He aims to establish a research network with other universities to collaborate and eventually bring the treatment to patients.
RECOMMENDED: Clint man sentenced to nearly 10 years for illegal immigrant smuggling conspiracy
Sign up to receive the top interesting stories from in and around our community once daily in your inbox.